David Nicholson from Allergan: Cariprazine Aims to Further Antipsychotic Market for Mental Health

Allergan has made a name for itself in the treatment of many neurological and mental health conditions and continues to grow its portfolio. One of its newest offerings is cariprazine which they hope will be a powerful tool in the antipsychotic area.

C. David Nicholson, PhD, Chief R&D Officer for the company discussed this new medication during the American Psychiatric Association's annual meeting in Atlanta. The medication was approved last year for schizophrenia and bi-polar disorder according to Nicholson who also said they are working to find potential new uses for the medication with their partner Gedeon Richter.